VERTEX PHARMACEUTICALS INC / MA Investment Income, Net
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Investment Income, Net of $120.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA investment income, net for the quarter ending 2026-06-30 was $120.60M, a 1.60% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA investment income, net for the quarter ending 2026-03-31 was $114.80M, a 2.63% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA investment income, net for the quarter ending 2025-06-30 was $118.70M.
- VERTEX PHARMACEUTICALS INC / MA investment income, net for the quarter ending 2025-03-31 was $117.90M.
| Period end | Investment Income, Net 3 month | Investment Income, Net 6 month |
|---|---|---|
| 2026-06-30 | $120.60M 10-Q · filed 2026-08-04 | $235.40M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $114.80M 10-Q · filed 2026-05-05 | |
| 2025-06-30 | $118.70M 10-Q · filed 2026-08-04 | $236.60M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $117.90M 10-Q · filed 2026-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |